Mercedes Segura Gally
VP Process Development, Editas Medicine
Mercedes Segura Gally is listed as VP Process Development, Editas Medicine. Mercedes is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Mercedes. Is this you? Claim this profile.
About
Mercedes Segura Gally, PhD, is Vice President of Process Development at Editas Medicine, where she leads the manufacturing strategy for in vivo gene-editing medicines. With over 20 years of experience in biopharmaceutical development, she has advanced programs from early research through commercial launch across multiple advanced therapeutic modalities. Her expertise spans mRNA and lipid nanoparticle (LNP) technologies, AAV and LVV viral vectors, and cell therapy manufacturing platforms. Previously, she held leadership roles at bluebird bio, AVROBIO, and ElevateBio. At bluebird bio, she contributed to the development and approval of Zynteglo®, Skysona®, Abecma®, and Lyfgenia®. She holds a Pharmacy degree and an MSc in Biotechnology from the Universidad de Buenos Aires, a PhD in Chemical Engineering from Université Laval, and completed postdoctoral research in bioprocessing at Universitat Autònoma de Barcelona, Spain.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Panel discussion: What is the data telling us about the clinical pathway to safe and efficacious in vivo gene therapy products? Speaker · 19 January 2027
- Session 1: How are key gene delivery platforms stacking up both in vivo and ex vivo to address concerns around safety, immunogenicity, durability, efficacy, and redosing potential? Speaker · 19 January 2027
- Panel discussion Speaker · 21 January 2027
- Session 9: Next-generation vector systems and emerging payloads – how and where can they enable the cell & gene therapy field to advance? Speaker · 21 January 2027
Spoke alongside
People who have shared a session with Mercedes at events on B2DB.
- Jeroen de Vrij CEO · ExoVectory 2 shared sessions
- Kate Excoffon American Society for Gene and Cell Therapy · American Society of Gene & Cell Therapy 2 shared sessions
- Mark Kay Dennis Farrey Family Professor, Departments of Pediatrics and Genetics; Head, Division of Human Gene Therapy · Stanford University 2 shared sessions
- Nathalie Clément Senior Vice President, Vector Development · Siren Biotechnology 2 shared sessions
- Sheena Smith Assistant Professor of Biotechnology, School of Chemistry, Chemical Engineering and Biotechnology (CCEB) · Nanyang Technological University, Singapore 1 shared session